Scalper1 News
Shares of early-stage development biotech Ligand Pharmaceuticals (LGND) rose 3.3% to 83.20 after it disclosed that it would receive higher royalty rates on drugs licensed to partner Viking Therapeutics, which on Friday re-filed terms for an IPO. The compounds covered under the amended licensing agreement are meant to treat hip fractures, anemia and metabolic and lipid disorders. The agreement also amended terms of upfront payments to Ligand for Scalper1 News
Scalper1 News